ontario regulation 499/05

made under the

ontario drug benefit act

Made: September 21, 2005
Filed: September 22, 2005
Printed in The Ontario Gazette: October 8, 2005

Amending O. Reg. 201/96

(General)

1. Section 1 of Ontario Regulation 201/96 is amended by adding the following subsection:

(7) For the purposes of this Regulation, items 392, 393, 394, 395, 396, 398, 1158, 1285, 1286 and 1287 of Part III of the Formulary shall be read as follows:

 

392	2265273	Novo-Warfarin 1mg Tab
393	2265281	Novo-Warfarin 2mg Tab
394	2265303	Novo-Warfarin 2.5mg Tab
395	2265311	Novo-Warfarin 3mg Tab
396	2265338	Novo-Warfarin 4mg Tab
398	2265346	Novo-Warfarin 5mg Tab
1158	2246083	Apo-Ipravent 0.03% Nasal Spray
1285	2245456	Sodium Aurothiomalate 10mg/mL Inj Sol-1mL Pk
1286	2245457	Sodium Aurothiomalate 25mg/mL Inj Sol-1mL Pk
1287	2245458	Sodium Aurothiomalate 50mg/mL Inj Sol-1mL Pk

2. The Regulation is amended by adding the following section:

7.2 A drug product identified by brand name and manufacturer in the following amendments to Part III of the Formulary is designated as a listed drug product unless there is an indication in that Part that the drug product is not a benefit:

1. Amendments dated September 30, 2005.

3. (1) Subject to subsection (2), this Regulation comes into force on September 27, 2005.

(2) Section 2 comes into force on the later of,

(a) September 30, 2005; and

(b) the day that is 10 days after the day of filing, where the following are not included in calculating the 10 days:

(i) the day of filing, and

(ii) Saturdays and Sundays and other holidays within the meaning of the Interpretation Act.

Made by:

George Smitherman

Minister of Health and Long-Term Care

Date made: September 21, 2005.